treatment
coronari
heart
diseas
utilis
lipid
modifi
modal
focus
lower
circul
level
lowdens
lipoprotein
cholesterol
ldlc
turn
drug
discoveri
effort
focus
investig
mechan
potenti
rais
highdens
lipoprotein
cholesterol
hdlc
plasma
belief
invers
relationship
hdlc
level
risk
coronari
heart
diseas
current
therapi
fibrat
niacin
exert
moder
effect
increas
hdlc
level
display
signific
side
effect
thu
remain
need
safer
efficaci
method
increas
hdlc
level
regard
cholesteryl
ester
transfer
protein
cetp
plasma
glycoprotein
secret
liver
investig
cetp
facilit
transfer
cholesterol
ester
hdl
ldl
vldl
exchang
triglycerid
furthermor
cetp
inhibit
lead
increas
hdlc
human
hdl
particl
accept
cholesterol
peripher
tissu
macrophag
thu
cetp
inhibitor
could
promot
revers
cholesterol
transport
therefor
antiatherogen
recent
work
led
identif
optimis
novel
seri
cetp
inhibitor
public
describ
screen
campaign
carri
use
fluoresc
assay
potent
compound
discov
evalu
activ
human
whole
plasma
assay
wpa
hit
ic
valu
lm
wpa
assay
obtain
start
point
investig
modular
structur
chemotyp
well
suit
rapid
explor
sar
applic
parallel
synthesi
strategi
involv
develop
chemistri
allow
explor
substitut
either
fuse
phenyl
benzoxazol
phenyl
ether
b
mark
synthet
strategi
studi
variou
ring
substitut
involv
format
two
amid
bond
deliv
compound
gener
structur
underw
microwav
assist
acidpromot
cyclis
anilidealcohol
use
ptoluenesulphon
acid
deliv
compound
gener
structur
averag
puriti
hplcuv
final
product
synthet
approach
use
vari
bring
proceed
via
format
anilin
explor
bring
parallel
synthesi
aryloxyacetyl
chlorid
provid
desir
product
gener
structur
altern
order
improv
rang
divers
contain
within
final
compound
anilin
acyl
chloroacetyl
chlorid
give
compound
underw
displac
chlorin
phenol
use
parallel
synthesi
give
desir
product
gener
structur
averag
puriti
determin
hplcuv
librari
sever
compound
obtain
display
reason
activ
one
potent
test
reveal
ic
lm
wpa
assay
pyrazol
potent
select
checkpoint
kinas
inhibitor
stratagem
use
battl
cancer
applic
treatment
caus
select
dna
damag
effect
cytotox
treatment
ionis
uv
radiat
chemotherapi
compromis
sever
side
effect
drug
resist
solut
problem
may
lie
sensitis
dnadamag
treatment
make
potent
andor
select
toward
tumour
cell
recent
studi
role
checkpoint
kinas
cell
cycl
respons
genotox
stress
studi
demonstr
inhibit
offer
mechan
sensitis
variou
dnadamag
therapi
human
serinethreonin
kinas
phosphoryl
upstream
kinas
atr
andor
atm
follow
dna
damag
subsequ
phosphoryl
induc
degrad
result
inhibit
downstream
cyclin
cyclin
kinas
lead
cell
cycl
arrest
phase
phase
respect
tumour
cell
arrest
differ
cell
cycl
checkpoint
mediat
chanc
repair
thu
inhibit
remov
checkpoint
caus
tumour
cell
undergo
prematur
mitot
entri
lead
cell
death
tumour
cell
normal
cell
differ
tumour
cell
often
defici
prevent
arrest
checkpoint
wherea
respons
dna
damag
normal
cell
capabl
arrest
checkpoint
pathway
ensur
genom
integr
differ
provid
potenti
therapeut
window
sensitis
dnadamag
treatment
cancer
use
inhibitor
recent
public
report
discoveri
pyrazol
new
class
kinas
inhibitor
program
use
screen
hit
start
point
design
compound
possess
ic
nm
xray
cocryst
structur
bound
activ
site
indic
project
team
focu
effort
elucid
sar
around
fluoro
group
occupi
region
extra
hydrogen
bond
inhibitor
sever
polar
residu
backbon
protein
could
envis
hittolead
process
undertaken
support
xray
crystallographi
round
medicin
design
number
potent
compound
obtain
possess
inhibitori
properti
one
potent
compound
possess
ic
valu
nm
compound
activ
enzymat
inhibit
assay
test
two
cellular
assay
cell
prolifer
assay
mt
assay
hela
cell
human
cervic
cancer
cell
line
use
measur
abil
inhibitor
sensitis
cell
dnadamag
agent
doxorubicin
ec
determin
inhibitor
singl
agent
inhibitor
combin
doxorubicin
ratio
rel
scale
inhibitor
abil
potenti
dnadamag
agent
addit
cell
cycl
analysi
fac
assay
cell
human
lung
cancer
cell
line
perform
determin
mechan
doxorubicin
sensitis
abrog
checkpoint
ec
either
concentr
inhibitor
reduc
doxorubicininduc
cell
popul
half
measur
absenc
doxorubicin
compound
possess
ec
lm
mt
assay
ec
nm
fac
assay
doxorubicin
present
summari
paper
month
issu
chemic
stabil
reactiv
bifunct
polym
conjug
contain
orthoamino
arylamid
linkag
success
exploit
achiev
parallel
synthesi
methoxycarbonyl
headtail
bisbenzimidazol
regioselect
alkyl
two
nitrogen
benzimidazolon
moieti
carri
ipsofluoro
displac
nalkyl
gener
two
divers
cleavag
polym
support
result
two
librari
diand
trisubstitut
benzimidazolyl
benzimidazolon
high
puriti
high
yield
solidphas
synthesi
sever
nalkyl
aicar
correspond
secoribosid
deriv
report
method
use
bound
solid
support
purin
base
strongli
activ
toward
attack
nnucleophil
allow
prepar
sever
alkyl
inosin
support
small
librari
aicar
deriv
synthesis
collect
small
molecul
reminisc
famili
long
chain
nacyl
tyrosin
enamid
enol
ester
isol
heterolog
express
environment
dna
edna
escherichia
coli
prepar
synthet
librari
nacyl
tyrosin
counterpart
prepar
via
solidphas
rout
wherea
enamid
enol
ester
synthesis
solutionphas
paper
month
posit
scan
synthet
combinatori
librari
employ
determin
conform
bicycl
guanidin
kappaopioid
receptor
activ
common
bioactiv
conform
put
pharmacophor
featur
suggest
mean
similar
method
comparison
model
known
opiat
suggest
similar
bind
mode
show
bicycl
guanidin
present
work
suitabl
scaffold
develop
new
opioid
receptor
ligand
wide
rang
commerci
diazodicarboxyl
phosphin
screen
attempt
find
purificationfre
condit
applic
parallel
synthesi
combin
immobilis
triphenylphosphin
tmad
prove
suitabl
synthesi
aryl
ether
via
mitsunobu
reaction
nine
ether
synthesis
good
yield
excel
puriti
three
polymersupport
quaternari
ammonium
mesyl
synthesis
use
recycl
polymer
phase
transfer
catalyst
ptc
compar
studi
use
nucleophil
fluorin
one
tertiari
alcoholcontain
polym
prove
best
catalyst
high
activ
chemoselect
facil
method
enantiosepar
functionalis
ger
base
analogu
possess
variou
substitut
pattern
develop
systemat
separ
librari
compris
repres
commerci
avail
chiral
stationari
phase
provid
valuabl
inform
structureenantioselect
relationship
onepot
twostep
protocol
microwaveassist
solidphas
synthesi
substitut
benzoxazol
develop
approach
start
differ
polymerbound
ester
previous
design
solidsupport
reagent
acyl
amin
alcohol
phenol
combin
parallel
synthesis
microwav
reactor
allow
rapid
prepar
collect
substitut
benzoxazol
high
puriti
satisfactori
yield
found
react
readili
alcohol
presenc
dbu
acid
tether
obtain
bear
free
carboxi
group
enabl
anchor
aminoalkyl
resin
also
structur
motif
allow
releas
target
alcohol
mild
hydrazinium
acet
treatment
nucleosid
derivatis
simpl
difunct
linker
arm
anchor
solid
phase
subject
synthesi
subsequ
releas
oligonucleotid
bear
basesensit
biodegrad
phosphat
protect
peptid
limit
use
drug
due
low
cell
permeabl
vulner
proteas
contrast
peptoid
immun
enzymat
degrad
peptoid
shown
rel
cell
permeabl
order
facilit
futur
design
peptoid
librari
screen
experi
strength
limit
highthroughput
cellbas
permeabl
assay
regist
rel
abil
steroidconjug
peptid
peptoid
enter
cell
assess
heteroaromat
one
librari
prepar
test
cytotox
properti
colon
cancer
cell
line
thu
provid
inform
pertain
structureact
relationship
class
compound
combin
literatur
survey
structurebas
virtual
screen
synthesi
small
librari
perform
identifi
hit
potenti
antimycobacteri
drug
target
glutamin
synthetas
base
one
hit
virtual
screen
small
librari
analogu
synthesis
produc
four
compound
inhibit
glutamin
synthetas
relat
proteinas
pro
pro
picornavirus
coronavirus
respect
good
drug
target
part
effort
gener
broadspectrum
inhibitor
enzym
librari
inhibitor
base
halopyridinyl
ester
prepar
three
compound
inhibit
cleavag
activ
hav
pro
k
ic
nm
among
potent
nonpeptid
inhibitor
report
date
pro
vancomycin
mainli
use
antibacteri
agent
last
resort
recent
vancomycinresist
bacteri
strain
emerg
recent
studi
aim
creat
new
antidrugresist
antibacteri
synthesis
step
inexpens
start
materi
sulpha
deriv
inhibit
dihydroptero
synthas
dhp
folat
pathway
would
act
folat
metabolitemim
inhibit
bacteri
folat
metabol
screen
sulphonanilid
librari
led
discoveri
benzenesulphonanilid
potent
antimethicillinresist
staphylococcu
aureu
mrsa
vancomycinresist
enterococcu
vre
activ
synthesi
vitro
evalu
librari
modifi
endomorphin
peptid
prepar
nand
ctermini
modifi
lipoamino
acid
laa
andor
sugar
overcom
metabol
instabl
poor
membran
permeabl
analogu
assess
lopioid
receptor
affin
inhibit
camp
accumul
enzymat
stabil
permeabl
across
cell
monolay
immobilis
staurosporin
aglycon
isoster
one
indol
nitrogen
atom
replac
carbon
sequenti
functionalis
gener
compound
inhibit
trka
kinas
first
phase
initi
screen
librari
result
sever
potent
compound
one
optimis
gener
correspond
carbam
solid
phase
insulinlik
growth
factor
receptor
growth
factor
receptor
tyrosin
kinas
act
critic
mediat
cell
prolifer
surviv
receptor
overexpress
activ
tumour
cell
emerg
novel
target
cancer
therapi
novel
seri
submicromolar
inhibitor
base
isoquinolinedion
templat
report
chemic
triag
parallel
synthesi
incorpor
focus
librari
array
instrument
move
discoveri
forward
synthesi
biolog
evalu
sar
depend
librari
novel
aryl
heteroaryl
substitut
n
propyl
inhibitor
kinas
describ
inhibitori
activ
synthesis
compound
highli
depend
charact
substitu
phenyl
ring
natur
termin
heterocycl
fragment
core
molecular
scaffold
molecular
duplic
nonnucleosid
revers
transcriptas
inhibitor
nnrti
narylthiocarbam
led
identif
symmetr
formimidoest
disulphid
novel
class
potent
nnrti
lead
compound
prevent
wildtyp
multipl
cell
cultur
ec
valu
lm
perform
structureact
relationship
studi
analogu
lead
compound
prepar
unpreced
onepot
method
solutionphas
parallel
synthesi
cyclodepsipeptid
jaspamid
interest
marin
metabolit
possess
potent
inhibitori
activ
breast
prostat
cancer
consequ
abil
disrupt
actin
cytoskeleton
dynam
recent
report
describ
synthet
modif
natur
metabolit
gener
small
array
unnatur
variant
